secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001213900-26-008204
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio updates on CORDStrom RDEB timing and XPro Alzheimer's Phase 2 results
--------------------------------------------------------------------------------

- CORDStrom commercial pilot runs completed; MAA to UK MHRA planned mid-2026; BLA to FDA targeted end of 2026.
- XPro Phase 2 MINDFuL missed primary endpoint in broad population (n=200) but showed cognitive effect (EMACC d=0.27) in biomarker-defined subpopulation (n=100).
- Cash position $27.7M as of Sept 30, 2025, expected to fund operations through year-end 2026.
- XPro reduced pTau217 and neuroimaging suggested reduced neurodegeneration in the subgroup.
- Regulatory timelines for CORDStrom and XPro remain subject to feedback and manufacturing readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/0001213900-26-008204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/ea0274317-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-008204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer